<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03954314</url>
  </required_header>
  <id_info>
    <org_study_id>DEPOSITION</org_study_id>
    <nct_id>NCT03954314</nct_id>
  </id_info>
  <brief_title>DEPOSITION - Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery</brief_title>
  <acronym>DEPOSITION</acronym>
  <official_title>Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery (DEPOSITION) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to conduct a double-dummy multi-centre randomized controlled clinical trial of
      application of topical dose of tranexamic acid (TxA) versus the usual intravenous TxA in
      patients undergoing on-pump cardiac surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative bleeding related to open cardiac surgery increases the rates of complications
      and mortality. It results from the blood thinners that are needed for use. Intravenous
      tranexamic acid (TxA) has become a mainstay in cardiac surgical procedures for decreasing
      bleeding and minimizing transfusion requirements. Although intravenous TxA is usually well
      tolerated, there is a well-known risk (1 to 4%) of postoperative seizures. This is due to the
      similarity between TxA and the brain tissues. The aim is to eliminate the risk of seizures
      but to maintain the protection against bleeding. When TxA is used directly on the tissues
      (topically) for other type of surgeries (joints), TxA is effective to reduce blood loss and
      transfusions. The aim is to prove that direct application of TxA on the heart can eliminate
      postoperative seizures and reduce the amount of blood transfusions in patients who have
      cardiac surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2019</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Tranexamic Acid intravenous + Placebo topical versus Placebo intravenous + Tranexamic Acid topical</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The pharmacy will prepare 2 syringes of 50 ml of topical TxA (5 g) or placebo. They will also prepare for the same patient 2 syringes of 50 ml (5 g) for intravenous (i.v.) injection or placebo. TxA is similar in all aspects to normal saline. Blinding of both teams will be easy. The syringes will be prepared and randomized in pharmacy before the surgery.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The composite of patients receiving in-hospital red blood cell transfusions or experiencing a seizure</measure>
    <time_frame>Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)</time_frame>
    <description>To determine in patients undergoing on-pump cardiac surgery, if topical tranexamic acid (intra-pericardial) is superior to the usual intravenous tranexamic acid administration for reducing the risk of in-hospital red blood cell transfusion or seizure (composite).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients in-hospital who receive red blood cell transfusions</measure>
    <time_frame>Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)</time_frame>
    <description>To determine whether topical tranexamic acid (intra-pericardial) compared with intravenous tranexamic acid administration reduces the risk of in-hospital red blood cell transfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients in-hospital who experience a seizure</measure>
    <time_frame>Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)</time_frame>
    <description>To determine whether topical tranexamic acid (intra-pericardial) compared with intravenous tranexamic acid administration reduces the risk of in-hospital seizure. The proportion of patients who experience a seizure will be analyzed using Fisher's exact test.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood product transfusions</measure>
    <time_frame>Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)</time_frame>
    <description>Analyzed using an ANCOVA model. In such a model, bags of blood product will be included as a dependent variable, whereas dose of tranexamic acid and treatment will be included as covariates.</description>
  </other_outcome>
  <other_outcome>
    <measure>Re-operation for bleeding or tamponade</measure>
    <time_frame>Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)</time_frame>
    <description>Analyzed with a binomial regression</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>Number of hours in ICU are being collected at the Post-Operative Visit. Hour collection will start upon arrival at ICU post surgery and stop at ICU exit, up to 10 days maximum.</time_frame>
    <description>Analyzed using an ANCOVA model.</description>
  </other_outcome>
  <other_outcome>
    <measure>MACE (Death, non-fatal Myocardial Infarction (MI), or non-fatal stroke)</measure>
    <time_frame>Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)</time_frame>
    <description>A Cox proportional hazard model will be used to analyze the time to the first occurrence of the composite of death, non-fatal MI, or non-fatal stroke (MACE).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3800</enrollment>
  <condition>Bleeding</condition>
  <condition>Surgical Blood Loss</condition>
  <condition>Seizures</condition>
  <arm_group>
    <arm_group_label>Topical Tranexamic Acid/Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical Tranexamic Acid 5g to 10g (50 to 100mL) or placebo. The topical will be poured into the pericardial and mediastinal cavities after protamine administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Tranexamic Acid/Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous Tranexamic Acid 1 to 10g (10 to 100mL) or placebo administered intravenously at the induction of anesthesia as a bolus-infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.</description>
    <arm_group_label>Intravenous Tranexamic Acid/Placebo</arm_group_label>
    <arm_group_label>Topical Tranexamic Acid/Placebo</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥ 18 years of age

          2. Undergoing a cardiac surgical procedure (i.e. isolated coronary artery bypass graft
             (CABG), isolated single cardiac valve surgery or a combination of both or isolated
             ascending aorta replacement) with the use of cardiopulmonary bypass (CPB) and median
             sternotomy

          3. Provide written informed consent

        Exclusion Criteria:

          1. Allergy to tranexamic acid

          2. Undergoing minimally invasive surgery

          3. Fulfill any of the following transfusion risk factors (A-D):

             A. Emergency surgery B. History of bleeding disorder C. Inherited thromboembolic or
             hemorrhagic disease D. Infective endocarditis

          4. History of previous cardiac surgery

          5. Severe renal impairment (serum creatinine &gt;250 µmol/L)

          6. Pre-operative hemoglobin &lt;120 g/L

          7. Pre-operative thrombocytopenia (&lt;50,000 platelets per µL)

          8. Expected circulatory arrest

          9. Pregnancy or breast feeding

         10. Previously enrolled in the DEPOSITION trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre Lamy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ingrid Copland, CCRA</last_name>
    <phone>905-527-4322</phone>
    <phone_ext>40368</phone_ext>
    <email>cogency@phri.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Austin Browne, PhD</last_name>
    <phone>905-527-4322</phone>
    <phone_ext>40582</phone_ext>
    <email>Austin.Browne@phri.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamilton Health Sciences - General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Power</last_name>
      <phone>905-521-2100</phone>
      <phone_ext>44495</phone_ext>
      <email>powerpat@hhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Andre Lamy, MD, MHSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Spence J, Long S, Tidy A, Raymer K, Devereaux PJ, Lamy A, Whitlock R, Syed S. Tranexamic Acid Administration During On-Pump Cardiac Surgery: A Survey of Current Practices Among Canadian Anesthetists Working in Academic Centers. Anesth Analg. 2017 Dec;125(6):1863-1870. doi: 10.1213/ANE.0000000000002422.</citation>
    <PMID>28858904</PMID>
  </reference>
  <reference>
    <citation>Lamy A, Tong W, Gao P, Chrolavicius S, Gafni A, Yusuf S, Connolly SJ. The cost of clopidogrel use in atrial fibrillation in the ACTIVE-A trial. Can J Cardiol. 2012 Jan-Feb;28(1):95-101. doi: 10.1016/j.cjca.2011.08.112. Epub 2011 Oct 8.</citation>
    <PMID>21983111</PMID>
  </reference>
  <results_reference>
    <citation>Habbab LM, Hussain S, Power P, Bashir S, Gao P, Semelhago L, VanHelder T, Parry D, Chu V, Lamy A. Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery (DEPOSITION) study: Results of a pilot study. J Card Surg. 2019 May;34(5):305-311. doi: 10.1111/jocs.14027. Epub 2019 Mar 25.</citation>
    <PMID>30908754</PMID>
  </results_reference>
  <results_reference>
    <citation>Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, Cooper DJ, Marasco S, McNeil J, Bussières JS, McGuinness S, Byrne K, Chan MT, Landoni G, Wallace S; ATACAS Investigators of the ANZCA Clinical Trials Network. Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. N Engl J Med. 2017 Jan 12;376(2):136-148. doi: 10.1056/NEJMoa1606424. Epub 2016 Oct 23. Erratum in: N Engl J Med. 2018 Feb 22;378(8):782.</citation>
    <PMID>27774838</PMID>
  </results_reference>
  <results_reference>
    <citation>Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussières JS, Côté D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R; BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008 May 29;358(22):2319-31. doi: 10.1056/NEJMoa0802395. Epub 2008 May 14. Erratum in: N Engl J Med. 2010 Sep 23;363(13):1290.</citation>
    <PMID>18480196</PMID>
  </results_reference>
  <results_reference>
    <citation>Mazer CD, Whitlock RP, Fergusson DA, Belley-Cote E, Connolly K, Khanykin B, Gregory AJ, de Médicis É, Carrier FM, McGuinness S, Young PJ, Byrne K, Villar JC, Royse A, Grocott HP, Seeberger MD, Mehta C, Lellouche F, Hare GMT, Painter TW, Fremes S, Syed S, Bagshaw SM, Hwang NC, Royse C, Hall J, Dai D, Mistry N, Thorpe K, Verma S, Jüni P, Shehata N; TRICS Investigators and Perioperative Anesthesia Clinical Trials Group. Six-Month Outcomes after Restrictive or Liberal Transfusion for Cardiac Surgery. N Engl J Med. 2018 Sep 27;379(13):1224-1233. doi: 10.1056/NEJMoa1808561. Epub 2018 Aug 26.</citation>
    <PMID>30146969</PMID>
  </results_reference>
  <results_reference>
    <citation>Kalavrouziotis D, Voisine P, Mohammadi S, Dionne S, Dagenais F. High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. Ann Thorac Surg. 2012 Jan;93(1):148-54. doi: 10.1016/j.athoracsur.2011.07.085. Epub 2011 Nov 4.</citation>
    <PMID>22054656</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tranexamic Acid</keyword>
  <keyword>On-pump Cardiac Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

